Absco Therapeutics (AbscoTx) is an MIT Langer Lab and Massachusetts General Brigham spin-out company developing a non-surgical, locally injectable immunotherapy depot to treat solid tumors, beginning with cervical precancer (CIN 2/3). Current treatment for the ~200,000 US women, ~6,500 Dutch women, and ~260,000 European women with CIN2/3 annually is surgical excision, which harms future reproductive health and fails to clear the underlying virus (HPV), leading to high recurrence. Instead, AbscoTx's approach trains a targeted immune response that can clear both the cervical lesion and HPV to prevent disease recurrence, without surgical excision or systemic toxicity.The lead asset, ABS005, uses a drug already clinically validated in CIN as a cream to facilitate rapid clinical translation. It is reformulated to enable local delivery with sustained cervical retention and to overcome previous vaginal tissue irritation limitations of the cream. Based on technology from MIT Langer and Traverso Labs, ABS005 uses a thermogelling polymer platform that is an injectable liquid at room temperature and transforms into a localized drug depot at body temperature for drug retention. This approach de-risks development and enables rapid clinical uptake, with expansion into other HPV-driven precancers and cancers including vaginal, vulvar, anal, and head and neck. Long term, we aspire to create a one-and-done treatment option where patients can simultaneously clear the lesion and the virus after a single in-office injection, removing fear of recurrence and enabling patients to treat their disease without impacting reproductive health.AbscoTx is a clinically-experienced company led by CEO Steve Linderman, MD, PhD, a practicing physician in the Harvard system, expert in targeted immune education using immunomodulatory biomaterials, and entrepreneur. Our EVP, David Altreuter, PhD brings 25 years of drug formulation and manufacturing experience with over a dozen products tested clinically. Morgan Stykel, PhD leads research strategy and operations. Board members and serial entrepreneurs Giovanni Traverso and Avik Som, both professors and physician scientists, bring extensive clinical and development experience with sustained drug delivery systems and immunotherapy. Dr. Jennifer Scalici advises as a leading gynecologic oncologist at Emory University focused on cervical lesions. Business advisors Christine Bunt and Jeff Finer, MD, PhD bring decades of experience as serial CEOs and investors with clinical drug development and entrepreneurship. The team brings diverse drug development expertise around a shared passion for advancing women’s health and cancer therapy.